Furthermore, MS patients who received administration of IFNβ revealed decreased mRNA for TNFα [43] and an increase in serum TNFRs, of which TNFR2 may play a protective role for myelin [44]. The gene discussed is TNFRSF1B; the disease is myeloid sarcoma.